 Homology Medicines NASDAQ:FIXX was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene correction, ... 